Medicine and Dentistry
Osimertinib
100%
Patient
100%
Non Small Cell Lung Cancer
66%
Epidermal Growth Factor Receptor
50%
Disease Exacerbation
33%
Epidermal Growth Factor Receptor Kinase Inhibitor
33%
Subgroup Analysis
33%
Central Nervous System Metastasis
33%
Therapeutic Procedure
33%
Combination Therapy
16%
Adverse Event
16%
Diarrhea
16%
Overall Survival
16%
Cancer Growth
16%
Silo-Filler's Disease
16%
Exanthem
16%
Progression Free Survival
16%
Coughing
16%
Treatment Duration
16%
Decreased Appetite
16%
Paronychia
16%
Central Nervous System
16%
Analysis
16%
Inpatient
16%
Pharmacology, Toxicology and Pharmaceutical Science
Osimertinib
100%
Non Small Cell Lung Cancer
66%
Epidermal Growth Factor Receptor
50%
Disease Exacerbation
33%
Epidermal Growth Factor Receptor Kinase Inhibitor
33%
Central Nervous System Metastasis
33%
Phase II Trials
33%
Adverse Event
16%
Cancer Growth
16%
Diarrhea
16%
Overall Survival
16%
Coughing
16%
Progression Free Survival
16%
Decreased Appetite
16%
Paronychia
16%
Lung Disease
16%
Rash
16%